Eterna Therapeutics Inc. (ERNA) Stock Forecast
ERNA analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $30.00 average of analyst targets
- Upside to target
- +1,335.4% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-3.84
- 52-week range
- $2.09 – $47.00
ERNA analyst ratings
1 analystsNumber of analysts at each rating.
ERNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ERNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.84 | −$3.84 | −$3.84 | — | — | 1 |
| Current fiscal year (2026) | −$18.02 | −$18.02 | −$18.02 | — | — | 1 |
| Next fiscal year (2027) | −$1.86 | −$1.86 | −$1.86 | −$18.02 | +89.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ERNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | — | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
ERNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ERNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$3.84 | −$3.84 | −$3.84 | −$3.84 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | −$18.02 | −$18.02 | −$18.02 | −$18.02 | — | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | −$1.86 | −$1.86 | −$1.86 | −$1.86 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ERNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ERNA beat in 0 of 6.
What analysts expect from ERNA
1 analysts cover Eterna Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $30.00, 1,335.4% above the latest close of $2.09. Analysts expect earnings of −$18.02 per share for 2026. For 2027 the average estimate is −$1.86 per share. Eterna Therapeutics beat the EPS estimate in 0 of the last 6 quarters.
Related: ERNA income statement, ERNA key metrics, ERNA chart. See the ERNA stock overview for the latest quote and news.
ERNA forecast FAQ
What is Eterna Therapeutics's price target?
The average analyst price target for Eterna Therapeutics is $30.00, 1,335.4% above the latest close of $2.09.
Is Eterna Therapeutics a buy, hold or sell?
Of 1 analysts covering Eterna Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eterna Therapeutics's EPS forecast?
Analysts forecast −$18.02 per share for 2026 (range −$18.02 to −$18.02); for 2027 the estimate is −$1.86.
When does Eterna Therapeutics report earnings?
Eterna Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 6, 2026; the EPS estimate is $-3.84.
Does Eterna Therapeutics usually beat earnings estimates?
Eterna Therapeutics reported EPS at or above the analyst estimate in 0 of the last 6 quarters.